Inhalation Sciences AB signs new distribution agreement with leading UK Labtech supplier
(Stockholm, Sverige, 11 April 2022) Inhalation Sciences AB has signed a new distribution agreement with Omicron Research Ltd, a leading supplier of dissolution instruments in the UK and Ireland. CEO Manoush Masarrat: “The UK is a key market with enormous potential. We welcome this new agreement.”
Omicron Research Ltd has a robust customer base in the UK and Irish pharmaceutical industry as a leading supplier of dissolution, chromatography and spectroscopy instruments. The company began life as the sales branch of a manufacturer of dissolution systems for oral solid drugs. The addition of ISAB to its roster will enable it to expand into R&D labs for inhaled drugs.
As well as ISAB’s leading dissolution technology DissolvIt®, Omicron Research will represent and actively promote ISAB’s entire product and service portfolio – from its flagship aerosol generator PreciseInhale®, with in vivo modules for exceptionally precise exposures, to its air-liquid interface instrument XposeALI® for permeability tests of biologics, to its contract research services under Inhalation Research Services.
Omicron Research Ltd’s General Manager Sam Stringer: “We are excited to be able to bring ISAB’s innovative products and research services to our marketplace to facilitate the growth of both our companies. The addition of ISAB to our portfolio allows us to strengthen our position in current industry sectors whilst providing the opportunity to expand into others.”
ISAB CEO Manoush Masarrat: “The UK and Ireland are both vital markets for us. We are confident that this new agreement will help increase our customer base and sales in these markets.”
For more information about Inhalation Sciences, please contact:
Manoush Masarrat, CEO
E-mail: Manoush.masarrat@inhalation.se
Mobile: +46 (0)73 628 9153
About Inhalation Sciences Sweden AB (publ)
Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company’s patented lab instruments PreciseInhale® and DissolvIt® enable researchers in the pharma industry to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, and so our health, when being inhaled.
Tags: